Sign In
Buy REGN
$628.73
+9.78 (+1.58%)
At Close: Jun 04, 2026
Regeneron Pharma's adjusted earnings beat estimates
06:49am, Thursday, 02'nd Nov 2023
Regeneron Pharmaceuticals Inc.'s stock REGN, +1.46% rose fractionally on Thursday after the drug maker said its profit dropped by 23%, while its adjusted results beat analyst expectations. Regeneron s
1 Supercharged Growth Stock That Could Make You a Millionaire in 10 Years
06:45am, Thursday, 02'nd Nov 2023
The healthcare sector has produced several of the best-performing stocks since World War II. The secret to their outperformance has been their laser-like focus on innovation.
Regeneron beats quarterly profit estimates on eczema treatment strength
06:42am, Thursday, 02'nd Nov 2023
Regeneron Pharmaceuticals on Thursday beat Wall Street estimates for third-quarter profit, driven by strong demand for its eczema treatment Dupixent.
Curious about Regeneron (REGN) Q3 Performance? Explore Wall Street Estimates for Key Metrics
12:47pm, Wednesday, 01'st Nov 2023
Besides Wall Street's top -and-bottom-line estimates for Regeneron (REGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the
Regeneron Announces Investor Conference Presentations
04:05pm, Wednesday, 25'th Oct 2023
TARRYTOWN, N.Y., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
2 Healthcare Stocks Near 52-Week Highs Still Worth Buying
09:26am, Monday, 16'th Oct 2023
Healthcare stocks, on balance, haven't been great investments in 2023. Regeneron Pharmaceuticals and Vertex Pharmaceuticals have been two glaring exceptions to this trend.
AI Stocks AVGO And ANET Lead 5 Resilient Names Near Buy Points
10:44am, Saturday, 14'th Oct 2023
AI stocks Broadcom and Arista lead five names near buy points all sporting a flat base, showing resilience in a tough market.
Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?
01:32pm, Friday, 06'th Oct 2023
Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
This Market-Beating Stock Just Gave Investors More Reasons to Invest
09:15am, Thursday, 05'th Oct 2023
Regeneron recently earned a key regulatory approval. The company also expanded its pipeline with an acquisition.
Here's the Best Big Pharma Stock of the Decade so Far (and It's Not Even Close)
05:50am, Thursday, 05'th Oct 2023
There have been relatively few big winners among pharma stocks so far in the 2020s. One big pharma stock stands out as the clear leader by roughly tripling over the last nearly four years.
Regeneron, Intellia Therapeutics expand research collaboration to make gene editing therapies
07:10am, Tuesday, 03'rd Oct 2023
Regeneron Pharmaceuticals and Intellia Therapeutics have expanded their research collaboration to develop additional CRISPR-based gene editing therapies focused on neurological and muscular diseases,
Stock Split Watch: Is Regeneron Pharmaceuticals Next?
05:30am, Saturday, 30'th Sep 2023
Regeneron's share price has climbed by more than 100% over five years and is trading near its record high. The company sells a variety of products across indications and has a solid pipeline that coul
Regeneron to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on November 2, 2023
04:05pm, Thursday, 28'th Sep 2023
TARRYTOWN, N.Y., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2023 financial and operating results on Thursda
Are Gene Therapy Stocks The Market's Next Big Winners?
08:06am, Monday, 25'th Sep 2023
It's not often that you see a company whose main product comes with a price tag of over $2 million, but that's the case with biotechs BioMarin Pharmaceutical NASDAQ: BMRN and Sarepta Therapeutics NASD
This Recent FDA Approval Could Give Regeneron's Top Line a Big Boost
10:07am, Wednesday, 20'th Sep 2023
Regeneron's sales growth rate has been struggling over the past year. Revenue from its top-selling drug, Eylea, fell 7% in the most recent quarter.
